Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival results from the randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study

被引：0

作者：

Lorusso, D. ^{[1
,2
]}

Xiang, Y. ^{[3
]}

Hasegawa, K. ^{[4
]}

Scambia, G. ^{[2
,5
]}

Leiva Galvez, M. H. ^{[6
]}

Elias, P. Ramos ^{[7
]}

Acevedo, A. ^{[8
]}

Bednarikova, M. ^{[9
,10
]}

Gomes, A. J. P. D. S. ^{[11
]}

Mejia, F. Contreras ^{[12
]}

Reiss, A. ^{[13
]}

Zagouri, F. ^{[14
]}

Lee, J-Y. ^{[15
]}

Saevets, V. ^{[16
]}

Ayhan, A. ^{[17
]}

Liu, P. ^{[18
]}

Yamada, K. U. ^{[18
]}

Puglisi, M. ^{[18
]}

Pignata, S. ^{[19
]}

Duska, L. ^{[20
]}

机构：

[1] Fdn Policlin Univ A Gemelli IRCCS, Gynaecol Oncol Unit, Rome, Italy

[2] Univ Cattolica Sacro Cuore, Rome, Italy

[3] Peking Union Med Coll Hosp, Natl Clin Res Ctr Obstetr & Gynecol Dis, Dept Obstet & Gynecol, Beijing, Peoples R China

[4] Saitama Med Univ, Gynecol Oncol Dept, Int Med Ctr, Saitama, Japan

[5] Fdn Policlin Univ A Gemelli IRCCS, Sci Directorate, Rome, Italy

[6] Inst Oncol & Radioterapia Clin Ricardo Palma, Med Oncol, Lima, Peru

[7] Edificio Integra Med Ctr, Integra Canc Inst, Guatemala City, Guatemala

[8] Oncocentro, Med Oncol, Vina Del Mar, Chile

[9] Univ Hosp Brno, Brno, Czech Republic

[10] Masaryk Univ, Fac Med, Brno, Czech Republic

[11] Liga Norte Riograndense Contra O Canc, Med Oncol & Med Oncol Res, Natal, Brazil

[12] Inst Nacl Cancerol, Clin Oncol, Bogota, Colombia

[13] Rambam Med Ctr, Gynecooncol Unit, Haifa, Israel

[14] Alexandra Gen Hosp, Clin Therapeut, Athens, Greece

[15] Yonsei Univ, Severance Hosp, Coll Med, Seoul, South Korea

[16] Chelyabinsk Reg Clin Ctr Oncol & Nucl Med, Dept Gynaecol, Chelyabinsk, Russia

[17] Baskent Univ, Turkish Soc Gynecol Oncol TRSGO, Ankara, Turkey

[18] Merck & Co Inc, Oncol, Rahway, NJ USA

[19] Ist Nazl Tumori IRCCS Fdn G Pascale, Dept Urol & Gynecol, Naples, Italy

[20] Univ Virginia, Obstet & Gynecol, Sch Med, Charlottesville, VA USA

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.771

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

709O

引用

页码：S544 / S544

页数：1

共 50 条

[41] Phase III Study for local or locally advanced Prostate Cancer: Randomized, double-blind, Placebo-controlled Phase 3 Study of Apalutamide in Patients with local High-Risk Prostate Cancer or locally advanced Prostate Cancer receiving primary Radiotherapy (ATLAS) - Study AP 90/15 of the AUO
Rexer, H.
Graefen, M.
Grimm, M. -O.
AKTUELLE UROLOGIE, 2017, 48 (06) : 520 - +
[42] KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (PBO) plus chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC).
Cortes, Javier
Guo, Zifang
Karantza, Vassiliki
Aktan, Gursel
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
[43] KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (PBO) plus chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)
Cortes Castan, J.
Guo, Z.
Karantza, V.
Aktan, G.
ANNALS OF ONCOLOGY, 2017, 28
[44] KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab versus placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk early-stage ER+/HER2-breast cancer
Cardoso, F.
Bardia, A.
Andre, F.
Cescon, D. W.
McArthur, H.
Telli, M.
Loi, S.
Cortes, J.
Schmid, P.
Harbeck, N.
Denkert, C.
Jackisch, C.
Jia, L.
Tryfonidis, K.
Karantza, V.
CANCER RESEARCH, 2019, 79 (04)
[45] Health-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG/Keynote 054 trial: An international randomized double-blind phase III trial
Coens, C.
Bottomley, A.
Blank, C. U.
Mandala, M.
Long, G. V.
Atkinson, V. G.
Dalle, S.
Haydon, A.
Lichinitser, M.
Khattak, A.
Carlino, M. S.
Sandhu, S. K.
Larkin, J.
Puig Sarda, S.
Ascierto, P. A.
Schadendorf, D.
Ibrahim, N.
Suciu, S.
Robert, C.
Eggermont, A. M. M.
ANNALS OF ONCOLOGY, 2018, 29 : 456 - 456
[46] KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) 1 chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)
Cortes Castan, J.
Guo, Z.
Karantza, V.
Aktan, G.
ANNALS OF ONCOLOGY, 2017, 28
[47] CYCLONE 3: A phase III, randomized, double-blind, placebocontrolled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer (mHSPC)
Mckay, R. R.
Agarwal, N.
Matsubara, N.
Rodriguez, J. M. Piulats
Smith, M. R.
Todenhofer, T.
Zhang, T.
Balar, A. V.
Schaverien, C.
Sherwood, S.
Johnston, E.
Lithio, A.
Nacerddine, K.
Sweeney, C. J.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1195 - S1196
[48] KEYNOTE-756: A Randomized, Double-blind, Phase 3 Study of Pembrolizumab or Placebo with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for High-Risk, Early-Stage, ER+/HER2-Breast Cancer
Hirshfield, Kim
Cardoso, Fatima
Bardia, Aditya
Andre, Fabrice
Cescon, David
McArthur, Heather
Telli, Melinda
Loi, Sherene
Cortes, Javier
Schmid, Peter
Harbeck, Nadia
Denkert, Carsten
Jackisch, Christian
Jia, Liyi
Karantza, Vassiliki
ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 2) : S288 - S288
[49] Double-blind randomized phase II results comparing concurrent high-dose cisplatin chemorradiation (CRT) plus debio 1143 or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN): A GORTEC study
Bourhis, J.
Sun, X.
Pointreau, Y.
Sire, C.
Le Tourneau, C.
Coutte, A.
Kaminsky-Forrett, M-C.
Alfonsi, M.
Boisselier, P.
Martin, L.
Delord, J-P.
Clatot, F.
Miroir, J.
Rolland, F.
Crompton, P.
Brienza, S.
Szyldergemajn, S. A.
Even, C.
Tao, Y.
ANNALS OF ONCOLOGY, 2019, 30 : 902 - 902
[50] Randomized, double-blind Phase-3 Trial of Apalutamide in Patients with localized or locally advanced High-risk Prostate Cancer scheduled for radical Prostatectomy PROTEUS - AUO Study AP 112/21
Rexer, Heidrun
Hammerer, Peter
Graefen, P.
AKTUELLE UROLOGIE, 2022, 53 (01) : 22 - 23

← 1 2 3 4 5 →